{
  "form": "10-Q",
  "filing_date": "2025--",
  "accession_number": "0000950170-25-070382",
  "company_name": "Company Name",
  "filing_url": "https://www.sec.gov/Archives/edgar/data/0000950170-25-070382",
  "content": "<SEC-DOCUMENT>0000950170-25-070382.txt : 20250513\n<SEC-HEADER>0000950170-25-070382.hdr.sgml : 20250513\n<ACCEPTANCE-DATETIME>20250513161537\nACCESSION NUMBER:\t\t0000950170-25-070382\nCONFORMED SUBMISSION TYPE:\t10-Q\nPUBLIC DOCUMENT COUNT:\t\t72\nCONFORMED PERIOD OF REPORT:\t20250331\nFILED AS OF DATE:\t\t20250513\nDATE AS OF CHANGE:\t\t20250513\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tRani Therapeutics Holdings, Inc.\n\t\tCENTRAL INDEX KEY:\t\t\t0001856725\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tPHARMACEUTICAL PREPARATIONS [2834]\n\t\tORGANIZATION NAME:           \t03 Life Sciences\n\t\tEIN:\t\t\t\t000000000\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t1231\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t10-Q\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t001-40672\n\t\tFILM NUMBER:\t\t25940331\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n\t\tBUSINESS PHONE:\t\t(408) 457-3700\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n</SEC-HEADER>\n<DOCUMENT>\n<TYPE>10-Q\n<SEQUENCE>1\n<FILENAME>rani-20250331.htm\n<DESCRIPTION>10-Q\n<TEXT>\n<XBRL>\n<?xml version='1.0' encoding='ASCII'?>\n<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->\n<!-- Creation Date :2025-05-13T15:28:19.1708+00:00 -->\n<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:xbrldi=\"http://xbrl.org/2006/xbrldi\" xmlns:xbrldt=\"http://xbrl.org/2005/xbrldt\" xmlns:xbrli=\"http://www.xbrl.org/2003/instance\" xmlns:link=\"http://www.xbrl.org/2003/linkbase\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:ix=\"http://www.xbrl.org/2013/inlineXBRL\" xmlns:nonNumeric=\"http://www.xbrl.org/dtr/type/non-numeric\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:dei=\"http://xbrl.sec.gov/dei/2024\" xmlns:us-gaap=\"http://fasb.org/us-gaap/2024\" xmlns:iso4217=\"http://www.xbrl.org/2003/iso4217\" xmlns:ecd=\"http://xbrl.sec.gov/ecd/2024\" xmlns:dtr-types=\"http://www.xbrl.org/dtr/type/2024-01-31\" xmlns:rani=\"http://www.ranitherapeutics.com/20250331\" xmlns:ixt-sec=\"http://www.sec.gov/inlineXBRL/transformation/2015-08-31\" xmlns:ecd-sub=\"http://xbrl.sec.gov/ecd-sub/2024\" xmlns:ixt=\"http://www.xbrl.org/inlineXBRL/transformation/2022-02-16\" xmlns:srt=\"http://fasb.org/srt/2024\" xmlns:utr=\"http://www.xbrl.org/2009/utr\">\n <head>\n  <title>10-Q</title>\n  <meta http-equiv=\"Content-Type\" content=\"text/html\"/>\n </head>\n <body style=\"padding:8px;margin:auto!important;z-index:0;position:relative;\">\n  <div style=\"display:none;\"><ix:header><ix:hidden><ix:nonNumeric id=\"F_39fa2c1e-9b93-4075-9708-03a76d952bd2\" name=\"dei:DocumentFiscalPeriodFocus\" contextRef=\"C_d0e8e895-b365-4fb4-80ff-965b9abb0740\">Q1</ix:nonNumeric><ix:nonNumeric id=\"F_70178a5b-eebc-40dc-b1aa-f20a91436932\" name=\"dei:EntityCentralIndexKey\" contextRef=\"C_d0e8e895-b365-4fb4-80ff-965b9abb0740\">0001856725</ix:nonNumeric><ix:nonNumeric id=\"F_4e3a4d42-0b82-4ada-8510-01a3c79d8cc8\" name=\"dei:AmendmentFlag\" contextRef=\"C_d0e8e895-b365-4fb4-80ff-965b9abb0740\">false</ix:nonNumeric><ix:nonNumeric id=\"F_ae02da7b-a28b-490e-9714-b0fed185d8c1\" name=\"dei:CurrentFiscalYearEndDate\" contextRef=\"C_d0e8e895-b365-4fb4-80ff-965b9abb0740\">--12-31</ix:nonNumeric><ix:nonFraction id=\"F_54ee5cc8-2cdf-49b4-a0b2-b0a2ed060542\" name=\"us-gaap:CommitmentsAndContingencies\" contextRef=\"C_83c38ecc-f143-4acc-9da4-d6c90ea0803f\" unitRef=\"U_USD\" xsi:nil=\"true\"></ix:nonFraction><ix:nonFraction id=\"F_e2c1fb55-03d4-4c9e-ae89-1f7bc76f44a5\" name=\"us-gaap:CommitmentsAndContingencies\" contextRef=\"C_83ccf098-7601-4d71-a38d-5a2278b57f88\" unitRef=\"U_USD\" xsi:nil=\"true\"></ix:nonFraction><ix:nonNumeric id=\"F_cefbe8cc-eee8-47d1-9524-2ae14555427d\" name=\"dei:EntityIncorporationDateOfIncorporation\" contextRef=\"C_d0e8e895-b365-4fb4-80ff-965b9abb0740\" format=\"ixt:date-day-month-year\">06-04-2021</ix:nonNumeric><ix:nonNumeric id=\"F_4f83794d-3373-4bfe-aac4-90d7571d3aaf\" name=\"rani:WarratsExpirationTerm\" contextRef=\"C_2c1f3ddb-be53-42ab-85bc-5b10917e38ae\" format=\"ixt-sec:duryear\">5.6</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type=\"simple\" xlink:href=\"rani-20250331.xsd\"/></ix:references><ix:resources><xbrli:context id=\"C_80a15e52-223c-4c30-bac9-cea3b66dee73\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension=\"us-gaap:StatementEquityComponentsAxis\">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id=\"C_834f1bb6-edfc-4f12-b74a-3c5bdd5b3661\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension=\"us-gaap:FairValueByAssetClassAxis\">rani:RestrictedCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension=\"us-gaap:FinancialInstrumentAxis\">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id=\"C_83c38ecc-f143-4acc-9da4-d6c90ea0803f\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id=\"C_83ccf098-7601-4d71-a38d-5a2278b57f88\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id=\"C_84764c05-dddc-4715-8548-e35dd8360b73\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension=\"us-gaap:StatementEquityComponentsAxis\">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id=\"C_850bfbdc-5d41-4caf-85ac-25bdb58cf159\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension=\"us-gaap:StatementEquityComponentsAxis\">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension=\"us-gaap:StatementClassOfStockAxis\">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id=\"C_863d941f-3661-4f18-a2e6-e1a974882cc5\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension=\"us-gaap:StatementEquityComponentsAxis\">rani:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id=\"C_87058558-2b78-4656-a64e-f427055eecd3\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension=\"us-gaap:FairValueByFairValueHierarchyLevelAxis\">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension=\"us-gaap:FinancialInstrumentAxis\">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension=\"us-gaap:FairValueByMeasurementFrequencyAxis\">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id=\"C_88bda3d7-90c1-4f72-a505-32266a80268f\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension=\"us-gaap:StatementClassOfStockAxis\">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id=\"C_895aa303-56f9-44b1-9185-0a2f424304eb\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension=\"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis\">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id=\"C_8b6ff375-b990-46eb-9fb1-0204ea77cc14\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension=\"us-gaap:IncomeStatementLocationAxis\">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id=\"C_8c96c2de-3222-474a-ab54-e1260506139e\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension=\"us-gaap:StatementEquityComponentsAxis\">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension=\"us-gaap:StatementClassOfStockAxis\">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id=\"C_8e411df8-cf47-46ad-9af3-f739df6a88fb\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension=\"us-gaap:CashAndCashEquivalentsAxis\">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMembe"
}